Department I of Internal Medicine, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
Infection. 2019 Apr;47(2):293-300. doi: 10.1007/s15010-019-01271-z. Epub 2019 Jan 28.
Rituximab (RTX) has been classified as a drug associated with a high risk for hepatitis B virus (HBV) reactivation in HbsAg-negative/anti-HBc-positive patients. However, data on frequency of HBV reactivation are limited especially for RTX monotherapy. Several new recommendations for screening, monitoring and prophylactic antiviral treatment have been published recently. Here, we report the real-life experience in the management and reactivation rate of HbsAg-negative/anti-HBc-positive patients treated with RTX with or without chemotherapy from a large cohort and discuss our results in the light of updated recommendations.
利妥昔单抗（RTX）已被归类为一种与乙型肝炎病毒（HBV）再激活相关的高风险药物，在 HBsAg 阴性/抗-HBc 阳性患者中。然而，关于 HBV 再激活频率的数据尤其有限，特别是对于 RTX 单药治疗。最近已经发表了一些关于筛查、监测和预防性抗病毒治疗的新建议。在这里，我们报告了来自大型队列的接受 RTX 联合或不联合化疗治疗的 HBsAg 阴性/抗-HBc 阳性患者的管理和 HBV 再激活率的真实经验，并根据最新建议讨论了我们的结果。
